We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immunovia Ab (publ) | LSE:0G8X | London | Ordinary Share | SE0006091997 | IMMUNOVIA ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 191.40 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | 1.65M | -309.44M | -6.8328 | -0.01 | 8.67B |
From Dec 2022 to Dec 2024
LUND, Sweden, Nov. 2, 2023 /PRNewswire/ -- Immunovia will publish its third quarter 2023 results on November 9, 2023 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com
Jeff Borcherding, CEO and President, and Karin Almqvist Liwendahl, CFO, will present on Immunovia's development. The presentation will be held in English and be followed by a Q&A session. You are welcome to join via webcast or phone, see details below.
Telephone numbers and webcast
Call any of the numbers below to participate via telephone. Please dial in a few minutes before the presentation starts.
Sweden: +46 (0)8 5051 0031
United Kingdom: +44 (0) 207 107 06 13
United States: +1 (1) 631 570 56 13
Link to the webcast: https://access.creomediamanager.com/registration/10534c57-ff26-4cd2-8e58-91ffc103b244?ref=https%3A%2F%2Fcreo-live.creomediamanager.com%2F10534c57-ff26-4cd2-8e58-91ffc103b244
A recording of the presentation will be available on Immunovia's website.
For more information, please contact:
Karin Almqvist Liwendahl
CFO
kain.almqvist.liwendahl@immunovia.com
+46 70 911 56 08
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
The following files are available for download:
https://mb.cision.com/Main/13121/3868101/2403762.pdf | Press release (PDF) |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-immunovias-q3-presentation-301975567.html
Copyright 2023 PR Newswire
1 Year Immunovia Ab (publ) Chart |
1 Month Immunovia Ab (publ) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
